Literature DB >> 18419385

Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005.

Sandra S Chaves1, John Zhang, Rachel Civen, Barbara M Watson, Tina Carbajal, Dana Perella, Jane F Seward.   

Abstract

Approximately 1 in every 5 children who receives 1 dose of varicella vaccine may develop varicella disease, also known as breakthrough disease, if exposed to varicella-zoster virus. Currently, in communities with high vaccination coverage, varicella cases mostly occur in vaccinated individuals. We report on the first population-based description of the clinical and epidemiological characteristics of varicella in populations with increasing vaccine coverage between 1997 and 2005. In vaccinated children 1-14 years of age, varicella was most often mild and modified; the atypical disease presentation may result in diagnostic challenges to health care providers. However, despite the generally mild nature of these cases, approximately 25% caused >50 lesions, and some resulted in serious complications similar to those occurring in unvaccinated individuals. Continued surveillance of the risk and characteristics of breakthrough disease will be needed, to monitor the effect of the new 2-dose vaccine recommendation for children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18419385     DOI: 10.1086/522150

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Varicella zoster virus transmission in the vaccine era: unmasking the role of herpes zoster.

Authors:  Karen C Bloch; James G Johnson
Journal:  J Infect Dis       Date:  2012-03-27       Impact factor: 5.226

2.  A varicella outbreak in a school with high one-dose vaccination coverage, Beijing, China.

Authors:  Li Lu; Luodan Suo; Juan Li; Lijun Zhai; Qingxiu Zheng; Xinghuo Pang; Stephanie R Bialek; Chengbin Wang
Journal:  Vaccine       Date:  2012-06-09       Impact factor: 3.641

3.  Varicella-related hospitalizations in the United States, 2000-2006: the 1-dose varicella vaccination era.

Authors:  Adriana S Lopez; John Zhang; Cedric Brown; Stephanie Bialek
Journal:  Pediatrics       Date:  2011-01-03       Impact factor: 7.124

4.  Varicella Vaccination Among US Adolescents: Coverage and Missed Opportunities, 2007-2014.

Authors:  Jessica Leung; Sarah Reagan-Steiner; Adriana Lopez; Jenny Jeyarajah; Mona Marin
Journal:  J Public Health Manag Pract       Date:  2019 May/Jun

5.  Cervical dermatomal zona misdiagnosed as ulnar nerve entrapment.

Authors:  Celal Şalçini; Gülin Sunter; Seyit Ali Gumustas; Alper Evrensel
Journal:  BMJ Case Rep       Date:  2015-06-01

6.  Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?

Authors:  Joke Bilcke; Albert Jan van Hoek; Philippe Beutels
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

Review 7.  Severe varicella in persons vaccinated with varicella vaccine (breakthrough varicella): a systematic literature review.

Authors:  Jessica Leung; Karen R Broder; Mona Marin
Journal:  Expert Rev Vaccines       Date:  2017-02-28       Impact factor: 5.217

Review 8.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

9.  Varicella Vaccine Effectiveness in Preventing Community Transmission in the 2-Dose Era.

Authors:  Dana Perella; Chengbin Wang; Rachel Civen; Kendra Viner; Karen Kuguru; Irini Daskalaki; D Scott Schmid; Adriana S Lopez; Hung Fu Tseng; E Claire Newbern; Laurene Mascola; Stephanie R Bialek
Journal:  Pediatrics       Date:  2016-03-14       Impact factor: 7.124

10.  Varicella: epidemiological aspects and vaccination coverage in the Veneto Region.

Authors:  Vincenzo Baldo; Tatjana Baldovin; Francesca Russo; Marta Cecilia Busana; Cinzia Piovesan; Greta Bordignon; Aurore Giliberti; Renzo Trivello
Journal:  BMC Infect Dis       Date:  2009-09-08       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.